Home » Newsletters » BioWorld Science

BioWorld Science

July 14, 2014

View Archived Issues

Discovery of a novel target in Plasmodium species leading to antimalarial drug development

HD Biosciences and Marshall University form cancer drug discovery agreement

Researchers present promising preclinical data for HM-12525A

Ipsen, Galderma/Nestle expand aesthetic dermatology businesses

Dignity Sciences reports data from phase II trial of DS-107E in atopic dermatitis

Ventana and Merck KGaA collaborate on companion diagnostic test

Plexxikon discloses new c-Kit inhibitors for cancer

Researchers at ChemoCentryx patent new CCR1 receptor antagonists

U.S. team discloses new 5-HT2C receptor agonists

Researchers report in vivo data for ZP-GA-1

Alios BioPharma divulges new NS5B inhibitors for HCV infection

Pfizer patents new EZH2 inhibitors for cancer

BioChaperone Lispro demonstrates a faster onset of action than naive insulin lispro

Bristol-Myers Squibb reports novel Abeta inhibitors

Hanmi presents promising results for HM-71224

ProStrakan to acquire Archimedes Pharma

Topline data reported from coBRIM study of cobimetinib in combination with vemurafenib

Brexpiprazole NDA submitted for schizophrenia and major depressive disorder

European orphan drug designations awarded to isavuconazole

Celgene set to study CC-220 in pilot phase II trial for SLE

Sialix changes name

Pfizer studies PF-06743649 in new phase I program for gout

New clinical data on remogliflozin etabonate presented

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...